Recursion, Mila partner on tech-enabled drug discovery

By The Science Advisory Board staff writers

Digital biology company Recursion signed a multiyear deal with artificial intelligence (AI) research institute Mila to develop technology-enabled drug discovery.

Recursion leverages machine learning to unravel complex patterns of biology within biological datasets of more than 8 PB.

Under the deal, Recursion will open office space within Mila and build a team to improve its machine-learning capabilities. Mila's AI technology and experts will help Recursion improve the lives of patients while industrializing drug discovery.

Financial details of the collaboration were not disclosed.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?